72012-87-4

Upstream product

• 126-81-8 dimedone 
• 64-04-0 phenethylamine 

Downstream Products

• 586979-23-9 2-bromo-N-(5,5-dimethyl-3-oxo-cyclohex-1-enyl)-N-phenethyl-benzamide 
• 293329-77-8 9-(3,4-dimethoxyphenyl)-3,3,6,6-tetramethyl-10-(2-phenylethyl)-1,2,3,4,5,6,7,8,9,10-decahydroacridine-1,8-dione 
• 1293926-97-2 3-(5-ethylsulfenyl[1,3,4]thiadiazol-2-ylamino)-6,6-dimethyl-1-phenethyl-3-trifluoromethyl-3,5,6,7-tetrahydro-1H-indole-2,4-dione 
• 1467055-82-8 dimethyl 2-(4,4-dimethyl-6-oxo-2-(phenethylamino)cyclohex-1-en-1-yl)-1H-benzo[d]-imidazole-1,3(2H)-dicarboxylate 
• 1467055-74-8 diethyl 2-(4,4-dimethyl-6-oxo-2-(phenethylamino)cyclohex-1-en-1-yl)-1H-benzo[d]-imidazole-1,3(2H)-dicarboxylate 
• 606924-49-6 N-[6,6-dimethyl-2,4-dioxo-1-(2-phenylethyl)-3-trifluoromethyl-2,3,4,5,6,7-hexahydro-1H-indol-3-yl]-4-chlorobenzenesulfonamide 
• 89229-77-6 5,5-dimethyl-3-(N-methyl-2-phenethylamino)cyclohex-2-enone 

Relevant academic research and scientific papers

A novel method for the synthesis of 4-aryl-2-amino-3-cyano-1,4,5,6,7,8-hexahydro-7,7-dimethyl-5-oxo-N-phenylethylquinolines

3-Phenylethylamino-5, 5-dimethylcyclohex-2-en-1-one 2 on condensation with arylidenemalononitriles 3a-f gives 4-aryl-2-amino-3-cyano-1,4,5,6,7,8-hexahydro-7,7-dimetyl-5-oxo-N-phenylethylquinolines 4a-f. Compound 2 has been synthesized by the reaction of 5

Synthesis and Anticonvulsant Activity of Enaminone. 2. Further Structure-Activity Correlations.

This report continues the in-depth evaluation of methyl 4--6-methyl-2-oxocyclohex-3-en-1-oate, 1 (ADD 196022), and methyl 4-(benzylamino)-6-methyl-2-oxocyclohex-3-en-1-oate, 2, two potent anticonvulsant enaminones.These compounds were evaluated employing the amygdala kindling model.Neither 1 nor 2 was active against amygdala kindled seizures, further supporting the corneal kindled model as a definitive tool for antielectroshock seizure evaluation as previously reported.Additional intraperitoneal (ip) data on 1 revealed toxicity at 24 h at 100 mg/kg.Several active analogs have been prepared with the view to minimizing toxicity.In a special ip rat screen developed by the Antiepileptic Drug Development (ADD) Program, these newer analogs were evaluated for protection against maximal electroshock seizures (MES) at 10 mg/kg and neurotoxicity at 100 mg/kg.From this screen, several compounds were shown to be safer alternatives, the most notable was methyl 4--6-methyl-2-oxocyclohex-3-en-1-oate, 13.Compound 13 had an ip ED50 of 4 mg/kg in the rat and a TD50 of 269 mg/kg, providing a protective index (TD50/ED50) of > 67.By variation in the ring size, additional aromatic substitutions and the synthesis of acyclic analogs, these newer compounds provide a more definitive insight into the structure-activity correlation.CLOGP evaluation and molecular modeling studies are also provided to further elaborate the molecular characteristics of potential anticonvulsant enaminones.